| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,766 | 2,796 | 13:03 | |
| 2,774 | 2,784 | 27.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 12,800 | 375 | |||
| 12,500 | 455 | |||
| 9,990 | 1.400 | |||
| 9,900 | 100 | |||
| 5,500 | 2.000 | |||
| 5,100 | 200 | |||
| 2,836 | 474 | |||
| 2,832 | 474 | |||
| 2,828 | 948 | |||
| 2,782 | 6.180 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/ayj.htm [/URL] | ||||
| 6.180 | 2,774 | |||
| 948 | 2,726 | |||
| 474 | 2,722 | |||
| 474 | 2,718 | |||
| 200 | 2,600 | |||
| 1.000 | 0,037 | |||
| 1.068 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 10.344 | 1,219 | 12.606 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 27.03.2026 | 15:05:41 | 2,778 | 1.449 |
| 27.03.2026 | 15:05:41 | 2,778 | 3.900 |
| 27.03.2026 | 15:04:20 | 2,778 | 1.091 |
| 27.03.2026 | 14:53:28 | 2,794 | 120 |
| 27.03.2026 | 14:53:28 | 2,800 | 80 |
| 27.03.2026 | 14:53:28 | 2,800 | 20 |
| 27.03.2026 | 14:51:24 | 2,800 | 900 |
| 27.03.2026 | 13:19:29 | 2,798 | 318 |
| 27.03.2026 | 13:06:06 | 2,802 | 1 |
| 27.03.2026 | 11:33:31 | 2,840 | 222 |
| 27.03.2026 | 11:33:31 | 2,834 | 300 |
| 27.03.2026 | 11:33:31 | 2,834 | 2.100 |
| 27.03.2026 | 11:33:28 | 2,842 | 31 |
| 27.03.2026 | 10:32:11 | 2,800 | 1.656 |
| Tagesumsatz Xetra | +0,016 +0,58 % | 26.351 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:30 | Valneva: Überraschende Erkenntnisse, die Anleger jetzt kennen sollten | Hebelschein-Spekulant | |||
| Fr | Weekly Buzz: Corcept Therapeutics Wins FDA Nod In Cancer; Merck & Co. Acquires Terns Pharmaceuticals; Insmed Meets Trial Goals But Valneva Misses | 623 | AFX News | KENILWORTH (NJ) (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Japan, EU withdrawals, mergers, and clinical trial data readouts spanning lung disease... ► Artikel lesen | |
| VALNEVA Aktie jetzt für 0€ handeln | |||||
| Do | Valneva SE - 6-K, Report of foreign issuer | 48 | SEC Filings | ||
| Do | Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC | 57 | GlobeNewswire (USA) | ||
| Mi | VALNEVA SE - Eilmeldung am Abend: Bewegung im Schatten! | 92 | Maximilian Berger |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Fr | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | dpa-AFX | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| 15:14 | Protagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology Annual Meeting | ACCESS Newswire | One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further... ► Artikel lesen | |
| Fr | Monopar Therapeutics Inc.: Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update | GlobeNewswire (Europe) | WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen | |
| Fr | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.03.2026 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 27.03.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.03.2026.ISIN NameCA98420Q3061 XORTX... ► Artikel lesen | |
| 07:10 | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology | GlobeNewswire (Europe) | Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Halle (Saale) / Munich, Germany... ► Artikel lesen |